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Background. Scientific evidence suggests that diet plays a role in obesity and its 21 
comorbidities, partly via its interactions with the individual’s gut microbiota. Likewise, the 22 
individual’s microbiota influences the efficacy of dietary interventions to reduce body 23 
weight. However, we require a better understanding of the key components of the gut 24 
microbiota that are responsive to specific diets and of their effects on energy balance in 25 
order to use this information in practice. 26 
Scope and Approach. This review provides an up-to-date description of the influence  of 27 
dietary fibers and fat on gut microbiota and the mechanisms presumably mediating their 28 
effects on metabolic health.  We also discuss the main knowledge gaps and the need to gain 29 
greater understanding of the role of diet-microbe interactions in obesity and the associated 30 
comorbidities. 31 
Key Findings and Conclusions. Dietary fibers are major drivers of gut microbiota 32 
composition and function, stimulating the dominance of bacteria able to utilize these 33 
substrates as energy source, although effects vary depending on both the type of fiber and 34 
the individual’s microbiota. However, the key bacteria and the primary and secondary 35 
metabolic pathways mediating specific fiber-induced effects on the metabolic phenotype 36 
remain unclear, and this information is necessary to personalize fiber-based interventions.  37 
The literature also shows that gut microbiota contributes to the adverse consequences of 38 
high-fat diets on the metabolic phenotype; however, little is known about the effects of 39 
dietary fat type. Further progress is expected from translational approaches integrating 40 
controlled dietary intervention human trials, combining functional omics technologies and 41 
physiological/clinical endpoints, and mechanistic studies in experimental models. This will 42 
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ultimately help us to progress towards establishing informed microbiome-based dietary 43 
recommendations and interventions, which can contribute to tackling the obesity epidemic 44 
and its comorbidities.  45 
Key words: Gut microbiota, microbiome, fiber, fat, diet-related diseases, obesity.  46 




Obesity has reached pandemic dimensions affecting a vast number of people worldwide. In 49 
2014, approximately 39% of adults (1.9 billion) were overweight and 13% of these (600 50 
million) were obese. Moreover, 42 million children under the age of 5 were reported as 51 
overweight or obese in 2013(World Health Organization, 2015). It is well known that 52 
obesity is not only associated with populations in high-income countries, but the prevalence 53 
is continuously growing in low- and mid-income countries, particularly in urban settings 54 
(World Health Organization, 2015). Obesity is a result of an unbalance between energy 55 
intake and expenditure, to which over-nutrition and a sedentary lifestyle are major 56 
contributors (Coppinger, Jeanes, Dabinett, Vogele, & Reeves, 2010). Obesity is associated 57 
with a state of chronic low-grade inflammation, which partly explains the insulin resistance 58 
phenotype observed in many obese individuals. In turn, insulin resistance is a component of 59 
the metabolic syndrome that often precedes the development of type 2 diabetes (T2D) and 60 
cardiovascular disease (CVD) (Jia, DeMarco, & Sowers, 2016). This metabolic 61 
inflammation is characterized by infiltration of macrophages and lymphocytes in peripheral 62 
tissues. This is accompanied by an increased production of pro-inflammatory cytokines, 63 
adipokines, acute-phase proteins and other immune mediators as a consequence of the 64 
activation of several signalling pathways, including the nuclear factor kappa B 65 
(NFκB)/Inhibitor of the kinase (IKK), c-jun N-terminal kinase (JNK), protein kinase R 66 
(PKR) and theToll-Like receptors (TLRs) (Gregor & Hotamisligil, 2011). Adipose tissue 67 
from obese individuals is considered to be the main contributor to obesity-related metabolic 68 
inflammation, with the highest accumulation of infiltrating macrophages and tissue 69 
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concentrations of cytokines, with similar events occurring in the liver and central nervous 70 
system, contributing to systemic insulin resistance (Johnson & Olefsky, 2013). 71 
In the last decade, an increasing number of studies have reported that obesity is associated 72 
with alterations in gut microbiota structure, suggesting that specific microbial taxa could be 73 
contributing factors to the obesity epidemic, although results are not fully consistent across 74 
human observational studies (Sanz, Rastmanesh, & Agostoni, 2013). Animal studies have 75 
provided information about the mechanisms by which gut microbiota could play a role in 76 
obesity, including contribution to nutrient digestion and absorption and to regulation of 77 
immune and neuro-endocrine functions (Moya-Perez, Neef, & Sanz, 2015). Experimental 78 
models have also demonstrated that gut microbiota can transmit the obesity-associated 79 
metabolic phenotype of its original human host when transferred to a germ-free recipient, 80 
providing a first evidence of causality (Turnbaugh, et al., 2006). Furthermore, a unique 81 
fecal transplantation study in humans has also demonstrated that the transference of feces 82 
from a lean donor into subjects with metabolic syndrome beneficially influence glucose 83 
metabolism, confirming the causal role of gut microbiota (Vrieze, et al., 2010). 84 
Nonetheless, the role of gut microbiota in obesity seems largely dependent on diet-microbe 85 
interactions due to the fact that diet is a major modifiable factor influencing gut microbiota 86 
composition and function (De Filippis, et al., 2015; Flint, Duncan, Scott, & Louis, 2015). 87 
Indeed, experimental models revealed that such interactions contribute to obesity, for 88 
example, by increasing lipid absorption or aggravating adipose tissue inflammation 89 
independently of adiposity in the context of diets rich in saturated lipids (Caesar, Tremaroli, 90 
Kovatcheva-Datchary, Cani, & Backhed, 2015; Semova, et al., 2012). Furthermore, dietary 91 
reprograming of microbiota ameliorates development of metabolic dysfunction despite 92 
susceptible genotypes (Ussar, et al., 2015). Nevertheless, our understanding of how diet-93 
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microbe interactions influence energy balance, eating behavior and obesity in humans is 94 
still insufficient to transform this information into practical solutions to tackle obesity-95 
associated disorders.  96 
This review discusses the most recent data regarding the potential role of dietary fiber and 97 
fat in remodeling gut microbiota composition and function and, thereby, in programming 98 
metabolic health. It also addresses the main limitations that must be overcome to progress 99 
our understanding of the microbiome’s role in the chain of events causing obesity. Only on 100 
gaining a better understanding of the above, will we be able to speed up the translation of 101 
this information into informed microbiome-based dietary interventions and 102 
recommendations. 103 
 104 
1. Impact of dietary fiber on human physiology  105 
 106 
1.1. Dietary fiber: role in metabolic health and as  main fuel for gut microbiota. 107 
Dietary fiber is generally defined as non-digestible carbohydrates plus lignin, which include 108 
structurally different components including non-starch polysaccharides, resistant 109 
oligosaccharides (e.g. fructo-oligosaccharides [FOS], galacto-oligosaccharides [GOS]) and 110 
resistant starch (EFSA NDA Panel, 2010). Prebiotics are defined as dietary fibers that 111 
modify the composition and/or metabolic activity of gut microbiota, thereby conferring a 112 
benefit to the host (G. R. Gibson, 2004; G. R. Gibson, Probert, Loo, Rastall, & Roberfroid, 113 
2004). According to this definition, a wide variety of food ingredients can be classified as 114 
prebiotics such as GOS, FOS and longer inulin-derived fructans, xylo-oligosaccharides 115 
(XOS) and arabinoxylan oligosaccharides (AXOS); however this is based mainly on their 116 
impact on gut microbiota rather than on robust evidence of their effects on health-related 117 
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endpoints (Hutkins, et al., 2016). Dietary fiber is not digested by human enzymes and thus 118 
it reaches proximal colonic regions, where it constitutes the main energy source for obligate 119 
anaerobic bacteria, whose fermentative activity leads to the generation of  organic acids 120 
(lactic, succinic acid) and short-chain fatty acids (SCFA) (acetate, propionate and butyrate). 121 
Consequently, the quantity and quality of fiber is considered to be one of the main dietary 122 
determinants of gut microbiota composition and function (Scott, Gratz, Sheridan, Flint, & 123 
Duncan, 2013). The current recommendations on dietary fiber intake (25 g per day for 124 
adults) are based on their well-known role in regulating bowel habits (frequency of 125 
defecation), including native chicory inulin considered to be prebiotic (Hutkins, et al., 126 
2016). In addition, there is evidence for a role of dietary fiber and some prebiotics (inulin 127 
and oligofructose) in the reduction of  dietary glycemic responses and glycemic load, with 128 
favorable effects on metabolic risk factors. Furthermore, consumption of fiber-rich diets 129 
with fiber intake above recommendations is associated with a reduced risk of coronary 130 
heart disease and type 2 diabetes as well as improved weight maintenance (Bes-Rastrollo, 131 
Martinez-Gonzalez, Sanchez-Villegas, de la Fuente Arrillaga, & Martinez, 2006; EFSA 132 
NDA Panel, 2010; S. Liu, et al., 2000; Ludwig, et al., 1999; Ye, Chacko, Chou, Kugizaki, 133 
& Liu, 2012). Dietary fiber is thought to positively influence metabolic health through 134 
multiple mechanisms, although effects cannot be generalized as they vary depending on the 135 
type of fiber. The mechanisms of action include direct effects related to its physicochemical 136 
and structural properties (e.g. indigestibility, viscosity, etc.) and indirect effects mediated 137 
by the individual’s gut microbiota. For example, compared to digestible carbohydrates, 138 
insoluble and soluble fibers reach distal portion of colon with no major degradation by 139 
human enzymes leading to a significant reduction in postprandial glycemic responses due 140 
to their slower digestion (EFSA, 2014). Consequently, consumption of fiber improves the 141 
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glucose metabolism as a whole, which have direct impact on satiety and tip the balance 142 
towards oxidation instead storage metabolism (reviewed in (Koh-Banerjee & Rimm, 143 
2003)). Moreover, dietary fiber is considered to be very useful for weight loss/maintenance 144 
aims given its low energetics estimated to be ~1.91 kcal/g (8 kJ/g) in comparison with other 145 
macronutrients as digestible carbohydrates, (~4.06 kcal/g), proteins (~4.06 kcal/g), and fat 146 
(~8.84 kcal/g) (Menezes, et al., 2016). Soluble viscous fibers may also exert beneficial 147 
metabolic effects by their ability to form gels that delay gastric emptying, inhibit nutrient 148 
absorption and bile acid (BA) binding; altogether this may contribute to a decreased 149 
postprandial glycemic response and a reduction in body cholesterol stores due to increased 150 
synthesis of new BAs from cholesterol in the liver (Dikeman & Fahey, 2006). In addition, 151 
dietary fiber is thought to mediate other effects (e.g. satiety and anti-inflammatory effects) 152 
through activation of the fermentative activity of gut bacteria, and the generation of 153 
potentially beneficial metabolites (e.g. SCFAs), as explained in greater detail in section 3.  154 
 155 
1.2. Evidence of the influence of dietary fiber on gut microbiota from observational studies.  156 
The role of non-digestible carbohydrates in the gut microbiota is well exemplified by the  157 
differences in the infant’s gut microbiota between breast-fed and formula-fed infants and 158 
between infant formula supplemented or not with oligosaccharides, which mainly stimulate 159 
the growth of bifidobacteria (Closa-Monasterolo, et al., 2013; Hascoet, et al., 2011). These 160 
effects have also been well-established by comparing the gut microbiota of individuals 161 
from different geographical regions that consume rural diets (Africa and South America) 162 
rich in dietary fiber or Western diets (Europe and North America) rich in animal protein 163 
and fat(De Filippo, et al., 2010; Yatsunenko, et al., 2012). Acomparison of the microbiota 164 
between European and African children, consuming a fiber-rich diet, showed that the latter 165 
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have reduced abundance of Firmicutes and increased abundance of Bacteroidetes, 166 
particularly the Prevotella and Xylanibacter genera, known to have genes specialized in 167 
cellulose and xylan utilization, with parallel increased fecal concentrations of SCFAs. In 168 
contrast, Enterobacteriaceae species (Proteobacteria) were reduced in African compared 169 
with European children (De Filippo, et al., 2010). Another large study including healthy 170 
children and adults also revealed important differences in bacterial communities and 171 
functional gene repertoires between US subjects from metropolitan areas and those from 172 
countries with a rural lifestyle (Amazonas of Venezuela and Malawi), finding the genus 173 
Prevotella to be abundant in humans with a diet rich in corn and cassava and in US children 174 
not following a full western diet (Yatsunenko, et al., 2012). A more recent study comparing 175 
African Americans and rural South Africans, found that animal protein and fat intake was 176 
2-3 times higher in Americans whereas carbohydrate and fiber (mainly resistant starch) 177 
intake was higher in Africans. The same authors also reported diet-associated microbiota 178 
and metabolite changes that were related to colon cancer risk. While the American 179 
microbiota was dominated by Bacteroides, the African microbiota was dominated by 180 
Prevotella and higher levels of starch degraders, carbohydrate fermenters, and butyrate 181 
producers. Moreover, the American microbiota had higher levels of potentially pathogenic 182 
Proteobacteria (Escherichia and Acinetobacter) and BA deconjugators (Ou, et al., 2013). A 183 
recent Dutch population-based metagenomic study involving 1,135 subjects has associated 184 
higher diversity, functional microbiome richness and abundance of Bacteroidetes with 185 
higher intake of fruits and vegetables (source of dietary fiber), higher concentrations of 186 
high-density lipoprotein (HDL) and lower concentrations of fecal chromogranin A 187 
(Zhernakova, et al., 2016).  The total amount of carbohydrates in the diet was also 188 
positively associated with Bifidobacterium but negatively associated with Lactobacillus and 189 
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microbiome diversity (Zhernakova, et al., 2016). All in all, these observational studies 190 
reveal that long-term consumption of fiber-rich diets promotes the dominance of fiber-191 
degraders of the phylum Bacteroidetes and Actinobacteria (Bifidobacteriumspp.) and, more 192 
consistently, of Prevotella spp. and reductions in Proteobacteria; nevertheless, Bacteroides 193 
spp. seem to be adapted to both fiber-rich diets and diets rich in animal protein and fat, 194 
probably due to their versatile metabolic capabilities. Notwithstanding, these observational 195 
data only provide associations but not causal relationships between specific dietary habits 196 
and the predominance of specific bacterial taxa, which limits their value in practice. 197 
Furthermore, other relevant environmental factors such as hygiene, geography, and 198 
ethnicity that could be involved in the respective gut microbiota profile observed are not 199 
well assessed. 200 
A recent experimental study in animal models also suggests that the lack of dietary fiber 201 
leads to a substantial loss in gut microbiota diversity, which influences the ability of gut 202 
bacteria to be transferred from parents to offspring. It also revealed that simply restoring 203 
fiber consumption was not enough to reverse these effects since some bacterial groups 204 
failed to return to their previous levels (Sonnenburg, et al., 2016). These results have led to 205 
hypothesize that long-term dietary changes in industrialized countries could have altered 206 
the host-microbiota partnership and microbiome functionality, with an adverse long-term 207 
impact on health that could be transmitted from generation to generation (Sonnenburg, et 208 
al., 2016). Notwithstanding, evidence from systematic studies in humans is required to 209 
confirm this hypothesis. 210 
 211 
1.3. Evidence for the influence of dietary fiber on gut microbiota from intervention studies.  212 
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A summary is given in Table 1 of recent representative human dietary interventions 213 
investigating how most common types of dietary fibers contribute to remodeling the gut 214 
microbiota. The responsiveness and effects of dietary fibers may differ depending on the 215 
individual’s gut microbiota profile (Korpela, et al., 2014), suggesting the need to work 216 
towards defining more specific and personalized dietary interventions and 217 
recommendations.    218 
 219 
1.3.1. Effects of wholegrain (WG)-rich foods. Wholegrain cereals are composed of starch-220 
rich endosperm, germ, and bran with high plant-fiber content. During harvesting and food 221 
processing, these components must preserve their relative proportions as in the intact kernel 222 
(HEALTHGRAIN Consortium - http://www.healthgrain.org). Rice, wheat, maize, oats, and 223 
barley are the main whole grains consumed worldwide and some of them have been proven 224 
to reduce the risk of certain diet-related diseases such as obesity and CVD. A controlled 225 
cross-over study showeda bifidogenic effectupon consumption of 48 g/day maize-based 226 
WG breakfast cereals during 21 days (Carvalho-Wells, et al., 2010). This effect was 227 
observed exclusively for the intervention period and not sustained after completion of the 228 
WG diet, strongly indicating that WG fiber is predominantly used by Bifidobacterium spp. 229 
(Carvalho-Wells, et al., 2010). Similar results were obtained by Costabile and coworkers 230 
who reported increased bifidobacteria and lactobacilli in feces after daily consumption of 231 
WG wheat breakfast cereals (48 g/day) in comparison with non-WG cereal (Costabile, et 232 
al., 2008). More recent results have shown that a four-week dietary intervention with 60 233 
g/day WG barley flakes in healthy adults induced a significant increase in the genus Blautia 234 
and a less pronounced increase in the abundance of the genera Roseburia, Bifidobacterium 235 
and Dialister (Martinez, et al., 2013). Additionally, this study showed that WG barley, 236 
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brown rice and specially the combination of WG barley and brown rice reduced plasma 237 
interleukin-6 (IL-6) and postprandial glucose. Interestingly, Eubacterium rectale was 238 
significantly more abundant in volunteers showing improvements in postprandial blood 239 
glucose and insulin response, whereas abundance of Dialister species was associated with 240 
the highest improvements in IL-6 levels (Martinez, et al., 2013). 241 
 242 
1.3.2. Resistant starch (RS). Starch is the major component of the plant-derived foods and 243 
comprises an important part of the human diet. The starch is referred as resistant when it  244 
cannot be hydrolyzed by digestive enzymes of the human GIT. The RS can be classified 245 
into several types (RS1 to RS5) according to the physical or chemical reasons to be 246 
indigestible. The RS1 is contained inside whole grains and is physically inaccessible for 247 
digestion; the RS2 is also native starch but remains indigestible by its compact structure; 248 
the RS3, also known as retrograde starch, is obtained by slow re-crystallization prior to heat 249 
disruption on water; the RS4 is the chemically modified starch by cross-linking or 250 
esterification; and the RS5 is a mixture of starch with lipids with high stability (Ma & 251 
Boye, 2016). Early studies about the RS impact on gut microbiota indicated that 252 
administration of controlled diet including 22 g/day RS induces changes in gut microbiota 253 
mainly in the clostridia cluster including members of the Ruminococcus genus (Abell, 254 
Cooke, Bennett, Conlon, & McOrist, 2008). Interventions with  50-60 g/day RS3 increased 255 
the abundance of several Ruminococcus spp.  and especially Ruminococcus bromii and 256 
Eubacterium rectale (Walker, et al., 2011). Similar results were obtained when 33 g/day 257 
RS2 or RS4 were administrated in baked crakers to volunteers during 3 weeks. In this case, 258 
increased proportions of Bifidobacterium adolescentis and Parabacteroides distasonis were 259 
found to be induced  particularly by RS4 intake, whereas increased proportions of 260 
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Ruminococcus bromii and Eubacterium rectale were induced by RS2 consumption 261 
(Martinez, Kim, Duffy, Schlegel, & Walter, 2010). In addition, RS intake of has been found 262 
to improve lipid metabolism in individuals with metabolic syndrome and help to control 263 
waist circumference and fat mass in non metabolic syndrome individuals (Nichenametla, et 264 
al., 2014). These beneficial effects of RS on metabolic aspects are thought to be at least 265 
partially mediated by the microbiota induced changes but direct evidence still has to be 266 
provided.  267 
1.3.3. Inulin and FOS. Inulin and FOS, also called oligofructose or oligofructans, are types 268 
of fructo-polysaccharides that consist of several -linked D-fructosyl residues with a D-269 
glucose group at end of the extended saccharide chain. These differ in the polymerization 270 
degree, which may range from 2 to 60 fructose units. FOS are usually produced by 271 
degradation of inulin obtained primarily from artichoke and chicory plants. These are used 272 
in the food industry as sweeteners, texture modifiers and fibers. A number of intervention 273 
studies have shown that the effects of inulin and FOS on gut microbiota composition can be 274 
associated with modifications on health related outcomes or subrogated biomarkers (Table 275 
1). In adults and infants, it is generally reported that inulin and FOS intake increases the 276 
number of bifidobacteria, sometimes associated with changes in metabolic products (e.g. 277 
lactate) (Closa-Monasterolo, et al., 2013; Garcia-Peris, et al., 2012; Petry, Egli, Chassard, 278 
Lacroix, & Hurrell, 2012). In some studies, inulin or FOS-induced microbiota changes have 279 
also been correlated with indicators of metabolic health. For example, a three-month 280 
double-blind placebo-controlled intervention with a mixture ofinulin/oligofructose or 281 
maltodextrin (8 g twice daily in powder to be dissolved in warm drinks) in obese women, 282 
showed increased abundances of Bifidobacterium spp. and Faecalibacterium prausnitzii, 283 
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which correlated to reduced serum LPS (lipopolysacchraide) levels. Additionally, the 284 
researchers observed reductions of Bacteroides intestinalis, Bacteroides vulgatus and 285 
Propionibacterium spp., which correlated to modest changes in fat mass. Additionally, they 286 
found reductions in plasma LPS, fecal acetate and propionate concentrations, and fasting 287 
insulinemia (Dewulf, et al., 2013; Salazar, et al., 2015). A recent study has evaluated the 288 
role of agave inulin showing a dose-dependent bifidogenic effect. The consumption of 5 or 289 
7.5 g/day agave inulin in chocolate chews, primarily promoted the presence of B. 290 
adolescentis, B. breve, B. longum, and B. pseudolongum (Holscher, et al., 2015). Positive 291 
correlations were also detected between fecal butyrate concentrations and the dose of fiber, 292 
and between fecal butyrate concentration and Faecalibacterium abundance. These effects 293 
could be explained by cross-feeding interactions disclosed between bifidobacteria and 294 
Faecalibacterium (Moens, Weckx, & De Vuyst, 2016). Interestingly, a depletion of 295 
Desulfovibrio species was also identified as a consequence of agave inulin consumption 296 
(Holscher, et al., 2015), which could be of clinical relevance because increased 297 
Desulfovibrio species have been related to obesity and the associated endotoxemia (Xiao, et 298 
al., 2014; Zhang-Sun, Augusto, Zhao, & Caroff, 2015; Zhang, et al., 2009). 299 
 300 
1.3.4. GOS 301 
GOS are mainly produced through transgalactosylation reactions mediated by -302 
galactosidases using lactose or derivatives as substrate. GOS are often used to supplement 303 
infant formula due to their chemical and structural resemblance to human milk 304 
oligosaccharides. In infant formula, GOS have been shown to exert a bifidogenic effect 305 
(Giovannini, et al., 2014). In adults, the six-week administration of 5.5 g/day GOS powder 306 
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mixture dissolved in water to subjects with metabolic syndrome has been shown to reduce 307 
levels of Clostridium histolyticum, Desulfovibrio spp. and Bacteroides spp.(Vulevic, Juric, 308 
Tzortzis, & Gibson, 2013). These changes were accompanied by increases in 309 
Bifidobacterium spp. and reductions in inflammatory markers, including fecal calprotectin 310 
and plasma C-reactive protein (CRP) and in some metabolic parameters (e.g. plasma 311 
insulin, total cholesterol and triglycerides in males). 312 
 313 
1.3.5. Xylans and arabinoxylans. Arabinoxylans (AX) from cereals are cell wall 314 
components that constitute a major part of the dietary fiber fraction of cereal grains and 315 
thus, an important fiber source in the diet (McCleary, 2003). Enzymatic hydrolysis of AX 316 
either in the production of processed foods or by bacteria in the colon yields 317 
arabinoxylanoligosaccharides (AXOS) and xylooligosaccharides (XOS), both of which are 318 
proposed to be prebiotic fibers (Broekaert, et al., 2011). Additionally to the well known 319 
bifidogenic effect of AX, a fact in which is based its prebiotic potential (reviewed in 320 
(Riviere, Selak, Lantin, Leroy, & De Vuyst, 2016)), other AX-degrading bacteria in the 321 
human colon belong to the genera Roseburia and Bacteroides and include the butyrate 322 
producing Roseburia intestinalis (Chassard, Goumy, Leclerc, Del'homme, & Bernalier-323 
Donadille, 2007). These data are of interest since a higher relative abundance of butyrate-324 
producing bacteria and Bacteroides spp. has been reported in healthy individuals compared 325 
to patients with T2D or pre-diabetic subjects in some studies (reviewed in (Sanz, Olivares, 326 
Moya-Perez, & Agostoni, 2015)). Human intervention trials have also shown increased 327 
fecal abundance of Bifidobacterium spp. following intake of 4 g/day XOS during three 328 
weeks (Chung, Hsu, Ko, & Chan, 2007) and from 2.14 to 10 g/day AXOS (Cloetens, et al., 329 
2010; Francois, et al., 2012; Maki, et al., 2012). Furthermore, a higher abundance of this 330 
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genus has been reported in normal weight subjects compared to obese and T2D subjects in 331 
some observational studies (Schwiertz, et al., 2010; Wu, et al., 2010). 332 
 333 
2. Microbiome components involved in the utilization of dietary fiber 334 
Dietary intake of fibers may lead to enrichment and altered expression of microbial genes 335 
which encode proteins/enzymes of metabolic pathways involved in the utilization of dietary 336 
fiber and the production of potentially beneficial metabolites (e.g. SCFAs). It is necessary 337 
to identify and characterize these pathways in order to understand the components of the 338 
microbiota and the microbiome that may underlie health effects associated with dietary 339 
fiber intake. Members of the phyla Bacteroidetes and Firmicutes are specialized in the 340 
utilization of complex carbohydrates and are the main producers of SCFAs. Butyrate and 341 
propionate are the two most thoroughly investigated SCFAs in terms of their potential role 342 
in metabolic health. The production of these SCFAs may require the participation of 343 
different bacterial genera and species via cross-feeding mechanisms. For example, 344 
Bacteroides thetaiotaomicron can directly produce propionate and acetate, which then can 345 
be used by Eubacterium halli to produce butyrate (Mahowald, et al., 2009). Similar cross-346 
feeding mechanisms have been described between some Bifidobacterium spp. and 347 
Faecalibacterium prausnitzii leading to increased butyrate production (Rios-Covian, 348 
Gueimonde, Duncan, Flint, & de los Reyes-Gavilan, 2015). Figure 1 shows the pathways 349 
identified for bacterial production of butyrate by genomic and metagenomic analysis of the 350 
human gut microbiota (Mahowald, et al., 2009; Reichardt, et al., 2014; Vital, Howe, & 351 
Tiedje, 2014). A conventional genetic signature to explore both the enrichment and 352 
variability of butyrate producers is via analyzing the butyryl-CoA:acetate CoA-transferase 353 
gene (BCoAT gene) encoding the respective enzyme responsible for the last step in butyrate 354 
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production. Quantitative approaches indicate BCoAT gene enrichment in gut microbiota 355 
from individuals with a high intake of plant fiber, which is indicative of increased colonic 356 
butyrate production (Hippe, et al., 2011; Louis, Young, Holtrop, & Flint, 2010; Remely, et 357 
al., 2014; Vital, Gao, Rizzo, Harrison, & Tiedje, 2015). 358 
Additionally to genes encoding enzymes of pathways responsible for SCFA production, the 359 
detection of other genes involved in the uptake and degradation of complex polysaccharides 360 
could be useful to define the active bacteria and their mode of action in response to fiber 361 
intake. Pioneer studies regarding characterization of proteins involved in the utilization of 362 
complex carbohydrates by anaerobe gut bacteria have revealed the essential role of 363 
polypeptides encoded by Sus genes, extensively studied in B. thetaiotaomicron (Reeves, 364 
Wang, & Salyers, 1997). The Sus products were originally described as outer membrane 365 
proteins able to bind complex starch. Notwithstanding, the genetic context of their encoding 366 
genes has enabled the inclusion of glycoside hydrolases (GH) enzymes in the Sus repertoire 367 
of proteins, which collectively work to produce small oligosaccharides that are more easily 368 
imported by bacteria. Consequently, Sus genes have become useful to detect different 369 
polysaccharide utilization loci (PULs) in other Bacteroides species by comparative 370 
genomics approaches, allowing them to be studied in response to a wide variety of complex 371 
polysaccharides (reviewed in (White, Lamed, Bayer, & Flint, 2014)). Nowadays, research 372 
on carbohydrate utilization by gut bacteria is conceived as a cornerstone to understand their 373 
physiology and potential interactions and bidirectional communication with the host in 374 
health and disease. In this regard, the Carbohydrate Active Enzymes (CAZy) database 375 
(http://www.cazy.org/) is one of the most complete repositories describing the families of 376 
structurally-related catalytic and carbohydrate-binding functional domains of enzymes that 377 
bind, degrade, modify or create glycosidic bonds (Lombard, Golaconda Ramulu, Drula, 378 
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Coutinho, & Henrissat, 2013). Hierarchical classification of CAZy comprises 4 main 379 
families such as the Glycoside Hydrolase (GH, with 135 subfamilies reported at Nov 2016), 380 
the Glycosyltransferase (GT, with 101 subfamilies), the Polysaccharide Lyase (PL, with 24 381 
subfamilies), and the Carbohydrate Esterase (CE, with 16 subfamilies) family. All GH 382 
reported are classified according to the functional modules they contain, with the aim to 383 
determine sites of action (exo or endo-acting enzymes) or type of cleavage (- or -384 
glycosilases). Members of the phyla Bacteroidetes and Firmicutes are characterized by 385 
encoding the largest set of GH in their genomes, thus exhibiting a remarkable versatility for 386 
the utilization of different polysaccharides as carbon source (White et al 2014). These 387 
features convert species of such bacterial phyla into key players for degradation of complex 388 
polysaccharides in the human colon. Proof of this can be found in the studies performed in 389 
Flint's lab with Ruminoccocus bromii in which this bacteria was observed to present a 390 
specialized extracellular polypeptide complex, known as amylosome (Ze, et al., 2015). It 391 
was also found to be an indispensable member of the human gut microbiota, having a direct 392 
effect on energy recovery from a central component of diet, i.e., RS (Ze, Duncan, Louis, & 393 
Flint, 2012). However, Bifidobacterium (Actinobacteria) species are also well-known fiber 394 
fermenters. Although Bifidobacteria have fewer GHs encoded in their genomes than 395 
Bacteroidetes, they also exhibit a great versatility for the uptake and catabolism of 396 
oligosaccharides. This versatility is well exemplified in genome-wide expression analyses, 397 
which have disclosed a wide variety of genes appearing to respond specifically to different 398 
carbon sources (Andersen, et al., 2013; O'Connell, et al., 2013). In this context, we have 399 
recently described the genome response of B. pseudocatenulatum CECT 7765, a strain 400 
isolated from breast-fed babies, during utilization of lactulose-derived oligosaccharides. An 401 
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exhaustive inventory of GH enzymes present in the genome of this species have a set of 402 
open reading frames (ORFs) that seem to control the uptake and degradation of this 403 
digestion-resistant oligosaccharide (Benitez-Paez, Moreno, Sanz, & Sanz, 2016). 404 
Although GHs and related proteins appear to be the key traits to infer versatility of gut 405 
microbes for utilization of polysaccharides and their contribution to the production of 406 
fermentation end-products such as SCFAs, little is known about the effects of fiber 407 
fermentation on secondary metabolic pathways and the generation of other nutrients (e.g. 408 
amino acids and vitamins) and bioactive compounds. Some in vitro studies have reported 409 
that oligosaccharide fermentation also increases amino acid synthesis (Benitez-Paez, et al., 410 
2016; Sulek, et al., 2014). In particular, our study revealed that the utilization of GOS by B. 411 
pseudocatenulatum CECT 7765, using bacteria cultures, increased the production and 412 
extracellular accumulation of branched-chain amino acids such as leucine (Benitez-Paez, et 413 
al., 2016). Additional studies are, however, needed to understand the effects of the interplay 414 
between dietary fiber and amino acid metabolism in the large intestine and fully understand 415 
the metabolites resulting from the activity of the gut microbiota and their potential 416 
consequences on health beyond the well-known SCFAs.  417 
 418 
3. Effects of dietary fiber on metabolic health mediated by gut microbiota 419 
There is a wealth of human intervention studies with dietary fibers, but only a few of them 420 
have assessed the relationship between microbiota-induced changes and endpoints related 421 
to physiological functions and metabolism. Further studies are also needed that directly 422 
assess the effects of fiber-induced microbiota changes on metabolic outcomes, for example 423 
via fecal transplantation or via inoculation of specific bacterial consortia from humans into 424 
animal models. Consequently, there is still a large degree of uncertainty about to what 425 
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extent the effects attributed to dietary fibers on metabolic health are mediated by gut 426 
microbiota in humans, and which are the key species involved. Nonetheless, considerable 427 
mechanistic data are available from other animal study approaches, as summarized below. 428 
 429 
3.1. Gut barrier integrity, metabolic endotoxemia and inflammation 430 
Obesity and particularly the intake of a high-fat diet (HFD) are thought to lead to a leaky 431 
gut and metabolic endotoxemia (increased serum LPS levels) in animal models and to some 432 
extent in humans. This is assumed contributing to the low-grade chronic inflammation 433 
leading to metabolic dysfunction and disease (metabolic syndrome and T2D). In fact, LPS 434 
is a potently inflammatory bacterial antigen linked to common metabolic diseases (Conlon 435 
& Bird, 2015). LPS is an endotoxin consisting of three parts; lipid A, the oligosaccharide 436 
core and the O-antigen, with the lipid A causing endotoxicity. LPS is normally present in 437 
the human gut (≥1 g) and under normal conditions it does not cause negative health effects. 438 
In healthy humans the normal/low plasma concentration of LPS is 1-200 pg/ml, but 439 
increased levels have been found in subjects with obesity and diabetes (Erridge, Attina, 440 
Spickett, & Webb, 2007; Moreira, Texeira, Ferreira, Peluzio Mdo, & Alfenas Rde, 2012). 441 
LPS binds to TLR4 via CD14 on, for example, the membrane surface of immune cells 442 
leading to activation of genes that codify pro-inflammatory cytokines (e.g. TNF-α and IL-443 
6) involved in metabolic inflammation. Experimental models of obesity have shown 444 
prebiotic-induced increases in bifidobacteria and Akkermansia spp. associated with reduced 445 
endotoxemia and systemic inflammation (Cani, et al., 2007; Schneeberger, et al., 2015). 446 
These effects can be partly explained by the ability of those bacteria to ferment glycans 447 
leading to SCFA production and promoting local decrease of pH, which may modulate gut 448 
microbiota composition and inhibit the growth of enterobacteria, which may be a source of 449 
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LPS (Delzenne, Neyrinck, & Cani, 2013; Everard, et al., 2013). This effect could also be 450 
related to the role of SCFAs in strengthening the gut barrier function, which also reduces 451 
LPS translocation via different mechanisms, including modulation of expression and 452 
localization of tight-junction proteins, induction of endocrine peptide production (GLP-2) 453 
and modification of the intestinal levels of endocannabinoids (Everard, et al., 2013). 454 
SCFAs also play an anti-inflammatory role by regulating the size and function of the 455 
colonic regulatory T cells (Treg), specifically inducing Foxp3+IL-10–producing Tregs 456 
(Smith, et al., 2013). SCFAs may also interact with peroxisome proliferator-activated 457 
receptor (PPAR) γ, thereby inhibiting pro-inflammatory signal transduction pathways (e.g. 458 
nuclear factor-kappa B [NF-κB]) leading to reduction of downstream cytokine/chemokine 459 
production (IL-6, IL-8, and MCP-1) in intestinal epithelial cells and metabolic tissues (e.g. 460 
adipose tissue) (Mastrofrancesco, et al., 2014). Activation of PPARγ also seems to be 461 
crucial in orchestrating Treg accumulation and function in the adipose tissue, which play an 462 
important role in preventing inflammation and insulin resistance (Cipolletta, Cohen, 463 
Spiegelman, Benoist, & Mathis, 2015). Butyrate as well as other SCFAs, protects against 464 
the liver inflammation process associated with steatosis by inhibiting the NF-B activation 465 
and downregulating expression of TLR4 receptor (Mattace Raso, et al., 2013). The 466 
molecular mechanisms underlying SCFA modulation of NF-κB activity have recently been 467 
disclosed as related to JNK and p38 kinases, which control NF-B activity (Haghikia, et al., 468 
2015). However, we cannot discard additional mechanisms to control NF-B function 469 
involving acetylation/deacetylation of histones and the RelA (p65) monomer itself (Davie, 470 




3.2. Enteroendocrine secretion and appetite 473 
In obese animals fed inulin-type fructans, there is an increase in plasma anorexigenic 474 
peptides (peptide YY and glucagon-like peptide - GLP-1) and a decrease in the orexigenic 475 
peptide ghrelin, which increases satiety (reviewed in (Delzenne, et al., 2013)). In addition, 476 
supplementation with fructans in HFD-fed mice modulates neuronal activation within the 477 
arcuate nucleus, which can help to control food intake (Anastasovska, et al., 2012). These 478 
effects on anorexigenic peptide secretion could be mediated by interactions of SCFAs with 479 
G-protein receptors such as FFAR2 (GPR41) and FFAR3 (GPR43), which could explain 480 
induction of satiety and increased insulin sensitivity (Blaut, 2014). Also in humans, 481 
prebiotic interventions with fructans have led to increases in anorexigenic peptides and/or 482 
decreases in orexigenic (ghrelin) peptides (Cani, Joly, Horsmans, & Delzenne, 2006; Cani, 483 
et al., 2009; Parnell & Reimer, 2009; Verhoef, Meyer, & Westerterp, 2011), but effects on 484 
satiety have not always been consistent (Peters, Boers, Haddeman, Melnikov, & Qvyjt, 485 
2009).  486 
 487 
3.3. Adiposity, lipid and glucose metabolism 488 
Reduced adiposity in rodents due to dietary supplementation with inulin-type fructans or 489 
AX has also been attributed to the role of SCFAs in modulating PPARγ expression via 490 
interaction with the G-protein coupled receptor protein FFAR3 (Delzenne, Neyrinck, 491 
Backhed, & Cani, 2011). Interestingly, den Besten and co-workers found that SCFAs 492 
decrease PPARγ expression, thus promoting activity of the uncoupling protein 2 (UCP2) 493 
and, thereby, stimulating oxidative metabolism in liver and adipose tissue, insulin 494 
sensitivity and weight loss (den Besten, et al., 2015). Studies with inulin-type fructans have 495 
also shown they can decrease hepatic accumulation of triglycerides and/or cholesterol in 496 
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liver tissue. These effects have been associated with a decrease in sterol-response-element-497 
binding protein-dependent cholesterogenesis, lipogenesis, or changes in PPARα-driven 498 
fatty acid oxidation (reviewed in (Delzenne, et al., 2013)). The majority of studies show 499 
prebiotic administration also leads to improved fasting or postprandial glycemia due to the 500 
very low digestion rates of prebiotics compared with digestible carbohydrates (for review 501 
see (Roberfroid, et al., 2010)). In addition, SCFA-stimulation of GLP-1 secretion can also 502 
mediate an improvement in glucose metabolism, reducing obesity-related hepatic insulin 503 
resistance.  504 
In humans, intervention studies with fructans have reported modest effects on body weight 505 
and fat mass in obese adults, but simultaneous changes in microbiota were not considered 506 
to have any correlation (Genta, et al., 2009; Parnell & Reimer, 2009). Nevertheless, there 507 
are also reports of a lack of effect on body weight in obese children (Liber & Szajewska, 508 
2014).  On the other hand, a rapid improvement in glucose tolerance has been observed for 509 
individuals consuming WG barley the night prior to analysis. These results were thought to 510 
be caused by the high amount of soluble dietary fiber and resistant starch contained in 511 
barley kernels, which facilitated bacterial fermentation in the colon overnight and produced 512 
significantly higher levels of SCFAs. This was indirectly measured from breath H2 513 
excretion (Nilsson, Granfeldt, Ostman, Preston, & Bjorck, 2006). Moreover, recent results 514 
of this dietary intervention model indicate that the fiber-associated improvement of glucose 515 
metabolism is also associated with an increase in Prevotella spp. (Kovatcheva-Datchary, et 516 
al., 2015). 517 
 518 
4. Impact of dietary fat on gut microbiota and associated metabolic endpoints 519 
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Globally, an increase in dietary fat content is usually paralleled with a decrease in 520 
carbohydrates, including dietary fiber content, thus making it difficult to attribute the 521 
observed changes, at physiology or gut microbiota levels, exclusively to one of the 522 
macronutrients whose proportion is being increased. Consequently, a decreased abundance 523 
of butyrate-producing bacteria and lower fecal SCFA excretion following a HFD is most 524 
likely caused by a decrease in dietary carbohydrate intake. Therefore, major conclusions 525 
derived from future animal or human studies including HFD interventions must be 526 
addressed carefully in order to consider confounding effects regarding the proportions and 527 
energetics or other macronutrients administrated. 528 
 529 
4.1. Evidence from animal studies 530 
The role of gut microbiota in HFD-induced obesity was suggested through animal 531 
experiments involving germ-free mice fed a HFD, which were protected from obesity 532 
compared to conventionally raised mice (Rabot, et al., 2010), thus highlighting the role of 533 
microbiota in HFD-induced obesity. Furthermore, a study in mice by Hildebrandt and 534 
coworkers showed that changes in the gut microbiota composition were caused by  dietary 535 
fat content rather than the degree of obesity, suggesting that fat directly impacts on 536 
microbiota regardless of the metabolic phenotype (Hildebrandt, et al., 2009). Gut 537 
microbiota transferred to germ-free mice from conventionally raised mice resulted in 538 
weight gain and a higher relative abundance of Firmicutes and a lower abundance of 539 
Bacteroidetes when mice were fed a HFD compared to a low-fat chow diet from 16 weeks 540 
of age (Turnbaugh, Backhed, Fulton, & Gordon, 2008). Although differences established at 541 
phylum level are of limited value since each phylum comprise many different species 542 
which may potentially play many different functions, a common trait for HFD-feding 543 
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seems to be that it increases the Firmicutes:Bacteroidetes ratio (de Wit, et al., 2012; 544 
Hildebrandt, et al., 2009; Lam, et al., 2012; Turnbaugh, et al., 2008), although there is not 545 
complete consistency across studies (Lecomte, et al., 2015); this would also be due to 546 
experimental and environmental differences. A recent 16-week study in mice fed a HFD 547 
reports that the abundance of Akkermansia muciniphila was progressively and drastically 548 
decreased while other groups including Bifidobacterium spp. and Lactobacillus spp. 549 
showed a transient decrease. In contrast the abundance of Roseburia spp. and Bilophila 550 
wadsworthia increased after 12 and 16 weeks upon HFD, respectively (Schneeberger, et al., 551 
2015). Interesting, B.wadsworthia have been linked to insulin resistance and inflammation 552 
in humans (Brahe, et al., 2015). 553 
Animal studies have revealed different mechanisms by which HFDcould exert adverse 554 
effects, partly mediated by the microbiota, on the host metabolic phenotype. For example, 555 
diets rich in saturated fat may contribute to inflammation, a hallmark of metabolic 556 
dysfunction leading to metabolic syndrome and T2D, by promoting the expansion of 557 
pathobionts, reducing the proportion of protective bacteria, and promoting a leaky gut that 558 
in turn facilitates the translocation of bacterial products (e.g. LPS) causing immune 559 
activation (Caesar, et al., 2015; Delzenne, et al., 2011; Devkota, et al., 2012). In a recent 560 
study, HFD-induced microbiota changes were correlated with obesity-related inflammatory 561 
and metabolic biomarkers (Schneeberger, et al., 2015). Akkermansia muciniphila was the 562 
species showing the clearest inverse associations with inflammatory markers in the adipose 563 
tissue and also with biochemical/hormonal parameters in circulation (i.e., insulin, glucose, 564 
triglycerides and leptin). 565 
However, as the majority of the dietary fat is absorbed in the small intestine and does not 566 
serve as an energy source for gut microbes, the effect of fat on gut microbiota must be 567 
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partly mediated by indirect mechanisms. Increased fat intake also leads to increases in fat 568 
quantities and of BAs reaching the colon, and particularly the concentration and 569 
composition of BAs modulates the gut microbiota exerting antimicrobial effects (Islam, et 570 
al., 2011; Ridlon, Kang, Hylemon, & Bajaj, 2014). Primary BAs (e.g. cholic acid [CA] and 571 
chenodeoxycholic acid [CDCA] in humans and beta-muricholic acid [β-MCA] in mice) are 572 
sterol compounds synthesized from cholesterol in the liver, conjugated with taurine and 573 
glycine, and then secreted into the small intestine to emulsify lipids to facilitate their 574 
digestion and absorption. The majority of BAs are reabsorbed (enterohepatic recycling), but 575 
as increased fat intake leads to increased BA secretion, theoretically more BAs will escape 576 
enterohepatic recycling, and hence reach the large intestine. During the transit to the large 577 
intestine, primary BAs undergo deconjugation, oxidation of hydroxyl groups at C-3, C-7, 578 
andC-12, and 7α/β-dehydroxylation reactions mediated by intestinal bacterial enzymes, 579 
yielding secondary BAs such as deoxycholic acid (DCA), lithocholic acid (LCA), and β-580 
muri-deoxycholicacid. Bacterial bile salt hydrolases (BSH), e.g. produced by Clostridium 581 
spp, catalyze the first reaction on secondary BAs and this is a step necessary for the 582 
subsequent7α/β-dehydroxylation (Degirolamo, Rainaldi, Bovenga, Murzilli, & Moschetta, 583 
2014). Overall, the amount and composition of BAs are strongly influenced by gut 584 
microbiota and vice versa, and BA biotransformation has important biological 585 
consequences due to their role in dietary lipid absorption and as signaling molecules, 586 
modulating cholesterol and triglyceride metabolism and glucose and energy homeostasis 587 
(Degirolamo, et al., 2014; Staels & Prawitt, 2013). Secondary BAs have strong 588 
antimicrobial activity (e.g. damage of the bacterial cell membrane by interaction with 589 
phospholipids) due to their amphipathic properties. For example, DCA has 10 times the 590 
bactericidal activity of CA (Islam, et al., 2011), therefore an increase in the proportion of 591 
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secondary BAs following HFD very likely affects the microbiota composition. A rat study, 592 
evaluating the effect of adding CA at different doses compared with controls (no CA 593 
added), demonstrated adose-dependent increase of fecal BA and DCA (Islam, et al., 2011). 594 
Furthermore, a dose-dependent decrease in fecal SCFA concentration was observed along 595 
with a reduction in total bacterial count and an increase in Firmicutes at the expense of 596 
primarily Bacteroidetes. 597 
Dietary saturated fat compared to poly-unsaturated fatty acids (PUFAs) was also reported 598 
to favor taurine conjugation of hepatic BAs, which caused an expansion of δ-599 
Proteobacteria-type pathobionts, in particularly B. wadsworthia which is a sulfite-reducing 600 
bacterium exerting a cytotoxic effect on epithelial cells and activating Th1-type 601 
inflammatory response (Devkota, et al., 2012). 602 
Studies in rodent models of HFD-induced obesity have also shown that saturated fat 603 
reduces the mucus layer, which acts as the first barrier separating the immune system from 604 
microbial and antigen interactions that may activate an inflammatory response. This effect 605 
was parallel to a reduction in the abundance of Akkermansia spp., while administration of 606 
this bacterium reversed it, increasing mucus layer thickness, and thus suggesting a 607 
microbiota-mediated effect (Everard, et al., 2013). Other animal studies have reported 608 
correlations between HFD-induced changes in the microbiota and alterations in the 609 
expression of tight junction-related proteins, and in gut permeability. In mice a HFD has 610 
been shown to reduce the expression of the tight-junction-related protein zonula occludens 611 
(ZO)-1 mRNA (Cani, Delzenne, Amar, & Burcelin, 2008) associated leading to increased 612 
gut permeability measured by transepithelial resistance (Lam, et al., 2012). Additionally, 613 
decreased transepithelial resistance (i.e. increased gut permeability) was associated a drop 614 
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in the abundance of Lactobacillus spp. and augmented abundance of Oscillibacter spp. 615 
(Lam, et al., 2012).  616 
Animal studies also show that when a HFD is supplemented with either prebiotics (Cani, et 617 
al., 2007; Everard, et al., 2013; Serino, et al., 2012) or antibiotics (Cani, Bibiloni, et al., 618 
2008) the HFD-induced alterations in gut microbiota and metabolism are partially reversed, 619 
indicating that gut microbiota partly mediate the consequences of HF feeding.  620 
A few studies have investigated the effects of different dietary fatty acids (Lam, et al., 621 
2012; Lappi, et al., 2013; Simoes, et al., 2013). In mice, it has been shown that n-6 high fat 622 
diets do not increase insulin resistance, intestinal permeability and fat accumulation to the 623 
same degree as saturated fatty acid diets, which is possibly due to a lower increase in H2S-624 
producing bacteria (Lam, et al., 2012). Likewise, lower decreases in Bacteroidetes have 625 
been found under diets rich in n-3 or n-6, compared to diets rich in saturated fatty acids(T. 626 
Liu, Hougen, Vollmer, & Hiebert, 2012). 627 
 628 
4.2. Evidence from human studies 629 
Only a few human intervention studies have investigated the effects of HFD compared to 630 
low-fat diets(LFD) or the type of fat (saturated fat versus PUFAs) in relation to changes in 631 
gut microbiota and the metabolic consequences. As found in animal studies, total bacterial 632 
counts decrease in humans who consume a HFD (35-38 E%), compared to a LFD (23-27 633 
E%) over 24 weeks (Fava, et al., 2013). Moreover, low/moderate-fat intake appears to 634 
induce a higher abundance of Bacteroides spp. and/or Bifidobacterium spp., compared to 635 
high-fat intake in human intervention trials (Brinkworth, Noakes, Clifton, & Bird, 2009; 636 
Fava, et al., 2013). An energy-restricted HFD (58 E%), compared with an isocaloric 637 
moderate-fat diet (28 E %) was shown to increase the total number of anaerobes in the 638 
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moderate-fat group, but not in the high-fat group, but the ratio between anaerobe:aerobe 639 
remained unchanged in each group (Brinkworth, et al., 2009). Additionally, a study 640 
comparing high-fat and moderate-fat ad libitum diets (66 E% vs. 35 E%) over 4 weeks did 641 
not report any effect on the gut microbiota in terms of total bacterial count; however, the 642 
methodology used to study microbiota abundance was based on a limited number of 643 
species(Duncan, et al., 2007).  644 
As stated above , an increase in the intake of dietary fat is usually at expenses of  a decrease 645 
in that of simple or complex carbohydrates, making it difficult to attribute the observed 646 
effectexclusively to one of the macronutrients. O’Keefe and coworkers (O'Keefe, et al., 647 
2015) compared the effects on gut microbiota in a cross-over study with a 2-week diet 648 
period administering either African- or American-food. The switch from a rural African to 649 
an American-diet (52% fat, 21% carbohydrate, 27% protein, and 12% fiber) decreased the 650 
abundance of butyrate-producing bacteria and the production of acetate, propionate and 651 
butyrate (O'Keefe, et al., 2015). Similarly, Duncan and coworkers observeda higher 652 
abundance of Roseburia and Eubacterium and higher fecal excretion of butyrate in humans 653 
following a moderate fat diet compared to high-fat intake, with these changes in the gut 654 
microbiota and derived metabolites being positively correlated with carbohydrate intake 655 
(Duncan, et al., 2007). 656 
O’Keefe and coworkers also measured BA excretion and observed that the high-fat diet of 657 
Americans was associated with increased expression of microbial genes coding for the 658 
enzyme related to converting primary BAs to secondary BAs, whereas a dietary switch to a 659 
lower-fat diet reduced the abundance of these bacteria. Furthermore, excretion of the 660 
secondary BAs LCA and DCA was increased by the HFD. Also short-term consumption of 661 
diets composed entirely of animal (rich in fat and protein) or plant products (rich in fiber) 662 
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can rapidly alter gut microbial composition (David, et al., 2014). An animal-based diet 663 
increased the abundance of bile-tolerant microorganisms, including Alistipes, Bilophila, and 664 
Bacteroides species. By contrast this diet decreased the abundance of Firmicutes, including 665 
genus and species specialized in the utilization of polysaccharides (Roseburia, Eubacterium 666 
rectale, and Ruminococcus bromii). Furthermore, the animal-based diet increased the 667 
abundance of B. wadsworthia and secondary BAs. These findings support the observations 668 
in rodent models comparing diets rich in PUFA or saturated fat (D. L. Gibson, et al., 2015; 669 
Schneeberger, et al., 2015), suggesting similar mechanisms of action and similar metabolic 670 
effects.  671 
The relationship between PUFAs and the microbiota are even less well understood. A 672 
recent study in women with obesity and metabolic syndrome who consumed inulin-type 673 
fructans for 3 months reported that PUFA-derived metabolites were associated with 674 
Bifidobacterium spp., Eubacterium ventriosum, and Lactobacillus spp., and negatively 675 
correlated with serum cholesterol (Druart, et al., 2014). However, another human 676 
intervention study found that supplementation with n-3 fatty acids (180 mg EPA and 120 677 
mg DHA) for 6 weeks did not induce changes in the gut microbiota although it decreased 678 
insulin resistance and CRP (Rajkumar, et al., 2014). Unfortunately, amelioration of these 679 
metabolic parameters could not be directly associated with one specific fatty acid since 680 
only a mixture was tested. Therefore, further studies are needed to gain greater 681 
understanding of how the quality of dietary fat influences gut microbiota composition and 682 
function, and potential mediated effects on metabolism in humans.  683 
 684 
 Concluding remarks 685 
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Fiber is an instrumental dietary component that can be used to remodel gut microbiota 686 
composition and function to potentiate the beneficial effects of healthy diets on body 687 
weight management and metabolism. However, efforts are still needed to identify the 688 
optimal functional partnership between key bacterial species and types of fibers, 689 
considering the specificities of the individual’s microbiota. Fermentation of dietary fiber 690 
generates SCFAs, which presumably articulate beneficial effects in the context of obesity; 691 
yet many other secondary metabolic products resulting from diet-microbe interactions have 692 
yet to be discovered. Gut microbiota appears to contribute to the adverse consequences of 693 
high-fat diets on the metabolic phenotype, aggravating the associated low-grade 694 
inflammation and increasing energy absorption; however, further studies are needed to 695 
understand the potential effects of the quality of dietary fat on the gut microbiota and 696 
secondary metabolic process, such as those involving bile acids and their signaling roles. 697 
Additional efforts must be conducted to identify the specific components of the gut 698 
microbiota, at species and  strain level,  influenced by different types of dietary fibers and 699 
fats and to understand their roles and mechanisms of action in humans to facilitate the use 700 
of this information in nutritional practice. This ambitious goal is expected to be 701 
accomplished by developing translational research approaches that integrate controlled 702 
dietary interventions in humans, combining functional omics technologies and 703 
physiological/clinical endpoints, and mechanistic studies in experimental models colonized 704 
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Figure Legends 1096 
 1097 
Figure 1.The bacterial butyrate synthesis pathways (adapted from (Vital, et 1098 
al., 2014)). Vital and coworkers have reconstructed four different pathways 1099 
for butyrate synthesis through and an extensive metagenomic approach. 1100 
Protein names and major substrates are shown across the different 1101 
biosynthetic pathways. Genes/proteins responsible of the last step of 1102 
butyrate production, and frequently used as biomarkers for gut microbiota 1103 
studies, are highlighted in red. They are known as: 4Hbt, butyryl-CoA:4-1104 
hydroxybutyrate CoA transferase; But, butyryl-CoA:acetate CoA 1105 
transferase; Ato, butyryl-CoA:acetoacetate CoA transferase (α, β subunits); 1106 






















































Table 1. Summary of dietary fiber interventional studies with gut microbiota assessments in humans. 
 
Fiber Study Design Subjects Time Gender Population Effects on gut microbiota1 Reference 
Maize-derived 
WG cereal 
DB, R, PC, CO 
 32 3 weeks 
Females (21) 
Males  (11) 
European 
UK ↑Bifidobacterium (Carvalho-Wells, et al., 2010) 
WG wheat cereal DB, R, PC, CO 31 3 weeks Females (16) Males (15) 
European 
UK ↑Bifidobacterium, Lactobacillus (Costabile, et al., 2008) 
WG barley R, CO 28 4 weeks Females (17) Males (11) USA 
↑Blautia,Bifidobacterium, Roseburia, 
Dialister 
↔Dialister- plasma IL-6levels 
↔Eubacterium- plasmaglucose/insulin 
(Martinez, et al., 2013) 
Inulin DB, R, PC, CO 32 4 weeks Females European Switzerland ↑Bifidobacterium (Petry, et al., 2012) 
Inulin (Agave) DB, R, PC, CO 29 3 weeks NA USA 
↑Bifidobacterium 
↓Desulfovibrio 
↔Faecalibacterium - fecal butyrate  
(Holscher, et al., 2015) 
Inulin / FOS DB, R, PC 31 8 weeks Females European Spain ↑Bifidobacterium, Lactobacillus (Garcia-Peris, et al., 2012) 
Inulin-type 






↔Bifidobacterium - plasma LPS levels 
↔Faecailbacterium - plasma LPS levels 
↔Bacteroides - Fat mass 
(Salazar, et al., 2015) 
Inulin / 






UK ↓Faecalibacterium, Bacteroides, Prevotella (Majid, et al., 2014) 
Inulin / 
Oligofructose DB, PC 30 12 weeks Females (44) 
European 
Belgium ↑Bifidobacterium, Faecalibacteriumprausnitzii (Dewulf, et al., 2013) 
Inulin / 




Spain ↑Bifidobacterium (Closa-Monasterolo, et al., 2013) 




↓Clostridium histolyticum, Desulfovibrio, 
Bacteroides 
(Vulevic, et al., 2013) 
GOS DB, R, PC, CO 31 3 weeks Females European The Netherlands ↑Bifidobacterium (Whisner, et al., 2013) 
GOS DB, R, PC 163 >16 weeks NA European Italy ↑Bifidobacterium (Giovannini, et al., 2014) 
XOS R, PC 22 3 weeks Females (7) Males (15) Taiwan ↑Bifidobacterium (Chung, et al., 2007) 
AXOS R, PC, CO 20 3 weeks Females (14) Males (6) 
European 
Belgium ↑Bifidobacterium (Cloetens, et al., 2010) 
AXOS DB, R, PC, CO 63 3 weeks Females (30) Males (33) 
European 
Belgium ↑Bifidobacterium (Francois, et al., 2012) 
AXOS DB, R, PC, CO 65 3 weeks Females (35) Males (30) USA ↑Bifidobacterium (Maki, et al., 2012) 
RS3 R, CO 14 3 weeks NA European Scotland ↑Ruminococcusbromii, Eubacteriumrectale (Walker, et al., 2011) 
2 
 
RS2, RS4 DB, CO 10 3 weeks Females (5) Males (5) USA 
↑ Bifidobacterium adolescentis, 




(Martinez, et al., 2010) 
RS R, CO 46 4 weeks Females (30) Males (16) Australia ↑Ruminococcusbromii (Abell, et al., 2008) 
1 Gut microbiota changes expressed in terms of abundance. ↑ indicates higher proportions of a determined bacterial genus after intervention, and ↓ indicates the 
inverse effect. ↔ indicates direct correlations among bacterial abundance and metabolic parameters studied, being negative or positive, respectively.DB= Double-
blind; Single-Blind = SB; R= randomized; PC = Placebo-controlled; CO = Cross-over; NA = No information was explicitly available for gender distribution into the 
intervention groups. 
